# Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg

> **NCT02662764** · PHASE3 · COMPLETED · sponsor: **Talphera, Inc** · enrollment: 320 (actual)

## Conditions studied

- Moderate-to-severe Acute Pain

## Interventions

- **DRUG:** Zalviso™ 15 mcg

## Key facts

- **NCT ID:** NCT02662764
- **Lead sponsor:** Talphera, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-28
- **Primary completion:** 2017-04-14
- **Final completion:** 2017-05-05
- **Target enrollment:** 320 (ACTUAL)
- **Last updated:** 2018-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02662764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02662764, "Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02662764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*